Katharina SCHMIDT-BLEEK,Hans-Dieter VOLK,Sebastian WENDLER,Georg N. DUDA,Simon REINKE,Sven GEISSLER,Taimoor Hasan QAZI,Anke DIENELT,Hanna SCHELL
申请号：
US16643538
公开号：
US20200197341A1
申请日:
2018.08.31
申请国别(地区):
US
年份:
2020
代理人:
摘要：
The present invention relates to a compound for use in a method for treating a musculoskeletal injury, wherein the compound is a regulator of the pro-inflammatory response and particularly being capable of upregulating regulatory T cells and/or M2-macrophages； and/or being capable of downregulating the biological activity of effector CD8+ cells, and further comprising the dosage regimen administering an initial dose of said compound to a patient not before 24 hours after said musculoskeletal injury.
